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Available online 28 April 2016The conserved internal inﬂuenza proteins nucleoprotein (NP) andmatrix 1 (M1) are well characterised for T cell
immunity, butwhether they also elicit functional antibodies capable of activating natural killer (NK) cells has not
been explored. We studied NP and M1-speciﬁc ADCC activity using biochemical, NK cell activation and killing
assayswith plasma fromhealthy and inﬂuenza-infected subjects. Healthy adults had antibodies toM1 andNP ca-
pable of binding dimeric FcγRIIIa and activating NK cells. Natural symptomatic and experimental inﬂuenza infec-
tions resulted in a rise in antibody dependent NK cell activation post-infection to the hemagglutinin of the
infecting strain, but changes in NK cell activation to M1 and NP were variable. Although antibody dependent
killing of target cells infected with vaccinia viruses expressing internal inﬂuenza proteins was not detected,
opsonising antibodies to NP andM1 likely contribute to an antiviralmicroenvironment by stimulating innate im-
mune cells to secrete cytokines early in infection. We conclude that effector cell activating antibodies to con-
served internal inﬂuenza proteins are common in healthy and inﬂuenza-infected adults. Given the signiﬁcance
of such antibodies in animal models of heterologous inﬂuenza infection, the deﬁnition of their importance and
mechanism of action in human immunity to inﬂuenza is essential.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Hemagglutinin1. Introduction
Seasonal inﬂuenza epidemics result in 30 to 50 million cases of se-
vere illness and 250 to 500 thousand deaths each year mainly in the
very young, the elderly and the chronically ill. To prevent inﬂuenza in-
fection a trivalent or quadrivalent vaccine, containing inactivated split
virion preparations from two inﬂuenza A viruses (H1N1 and H3N2)
and one or two inﬂuenza B viruses, is widely administered especially
to high-risk groups (World Health Organization, 2015). Inﬂuenza vacci-
nation primarily induces neutralising antibodies (NAbs) against the en-
velope protein hemagglutinin (HA) (Atmar et al., 2007; Martin Mdel
et al., 2010). NAbs bind to HA inhibiting viral attachment to cell surfaceand Immunology, University of
Immunity, 792 Elizabeth Street,
. This is an open access article undersialic acid and prevent viral fusion with host cells (Krause et al., 2011;
Wang et al., 2010). However the effectiveness of antibody-mediated
neutralisation is limited by the continual antigenic drift of the HA pro-
tein (Sandbulte et al., 2011; Shil et al., 2011). The accumulation of
mutations in HA and re-assortment events between antigenically dis-
tinct viruses (antigenic shift) can result in the emergence of inﬂuenza
variants not recognized by NAbs (Fielding et al., 2011; Hardelid et al.,
2011; Yang et al., 2012). To minimize the impact of antigenic change
the inﬂuenza vaccine is updated annually. Furthermore seasonal vacci-
nation is strain-speciﬁc and is only weakly protective against infection
with divergent inﬂuenza viruses. Global inﬂuenza pandemics can
occur when there is minimal immunity to novel inﬂuenza viruses capa-
ble of infecting humans (Peiris et al., 2009).
In addition to neutralisation, antibodies (Abs) mediate a number of
other effector functions through their Fc region. These functions include
complement activation (O'Brien et al., 2011; Ohta et al., 2011), Ab-
dependent phagocytosis (ADP) (Huber et al., 2001) and Ab-dependentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Time of pre- and post-seroconversion samples, CFT and HI titre for three naturally
inﬂuenza-infected patient sera samples received from the WHO Collaborating Centre
for Reference and Research on Inﬂuenza.
Patient Time point CFT result HI titre
H1N1 A/California/07/2009
1 Day 0 b10 b10
Day 17 N120 80
2 Day 0 10 b10
Day 16 N320 20
3 Day 0 10 b10
Day 12 N320 80
278 H.A. Vanderven et al. / EBioMedicine 8 (2016) 277–290cellular cytotoxicity (ADCC) (Greenberg et al., 1978; Hashimoto et al.,
1983a, 1983b; Vella et al., 1980). Natural killer (NK) cells are cytotoxic
lymphocytes of the innate immune system that play an important role
in the elimination of virally infected and transformed cells. ADCC is me-
diated when the NK cell FcγRIIIa (CD16a) receptor interacts with the
Fc region of IgG Abs bound to their viral antigens (Ags) on the surface
of virally infected cells. IgG-Fc region binding to and crosslinking of
FcγRIIIa leads to NK cell activation, which includes degranulation re-
leasing perforins and granzymes, as well as the secretion of anti-viral
cytokines such as IFNγ and TNF. It has been shown that ADCC Abs en-
hance protection against several clinically important viral pathogens
(Laoprasopwattana et al., 2007; Vogt et al., 2011; Xiao et al., 2010). Our
group has previously demonstrated that healthy inﬂuenza-exposed
adults have Abs to HAs from non-circulating strains of inﬂuenza in the
absence of NAbs. We have also shown that HA-speciﬁc Abs lead to NK
cell activation and inﬂuenza clearance in vitro (Jegaskanda et al.,
2013a, 2013b, 2013c, 2014a). There has been a recent interest in ADCC
Abs targetingmore conserved inﬂuenza surface Ags such as the extracel-
lular domain of matrix 2 protein (eM2) (El Bakkouri et al., 2011; Kim
et al., 2014; Lee et al., 2014) and the stalk region of HA (DiLillo et al.,
2014; Ellebedy et al., 2014; Margine et al., 2013a, 2013b).
Inﬂuenza proteins inside the viral envelope are highly conserved
across different strains and subtypes of inﬂuenza. Two internal proteins
that have been extensively studied in the context of inﬂuenza infection
are nucleoprotein (NP) and matrix protein 1 (M1). NP binds and trans-
ports the RNA genome of inﬂuenza and M1 is a structural protein that
coats the inside of the inﬂuenza virion. Both NP and M1 contain well-
characterized epitopes for CD4+ and CD8+ T-cell responses to inﬂuenza
virus infection.Ongoing studies aim to create a heterosubtypic inﬂuenza
vaccine by speciﬁcally inducing T-cell responses to conserved NP and
M1 epitopes (Chen et al., 2014; Hessel et al., 2014; Lambe et al., 2013;
Lillie et al., 2012). An additional role for Abs against internal inﬂuenza
proteins is starting to emerge. In animal models, NP-speciﬁc IgG and
vaccination with whole NP have successfully provided protection
against heterologous inﬂuenza challenge (Epstein et al., 2005; Lamere
et al., 2011a; Ulmer et al., 1993; Wraith et al., 1987). Passive transfer
of non-neutralising NP Abs can also fully protect against inﬂuenza chal-
lenge in mice, but themechanism of protection has yet to be elucidated
(Carragher et al., 2008; LaMere et al., 2011b). NP can also be found on
the surface of inﬂuenza-infected cells in vitro, along with barely detect-
able levels of M1 (Bodewes et al., 2013; Virelizier et al., 1977; Yewdell
et al., 1981). It is conceivable that non-neutralising Abs to M1 and NP
may be involved in clearance of infected cells through Fc mediated ef-
fector functions. Improving our understanding of the humoral response
to internal inﬂuenza proteins may contribute to the development of a
universally protective vaccination strategy. Herein we have demon-
strated M1 and NP Abs are a common feature of inﬂuenza-exposed or
infected human adults and these Abs have the ability to trigger activa-
tion of NK cells.
2. Materials and Methods
2.1. Donors and Plasma Samples
We studied healthy adults, subjects with clinical inﬂuenza virus in-
fection and subjects with experimental inﬂuenza virus infection for
NK cell activating Abs to internal inﬂuenza proteins. Fourteen healthy
donors were recruited to donate plasma samples from September
2013 to December 2014. The median age of the donors is 29.5, with a
range of 22–52. All of the donors had the trivalent inﬂuenza vaccine
one to 10 times since 2005. Plasma samples were also taken from four
inﬂuenza-naïve pigtail macaques (Macaca nemestrina) to serve as inﬂu-
enza Ab negative samples. Nine of the healthy donors recruited above
and one of the inﬂuenza-naïvemacaques were used in the recombinant
soluble FcγRIIIa ELISA described below. Plasma samples from two of
the healthy donors and one macaque were also tested in an NK cellactivation assay with puriﬁed primary NK cells. Macaque studies were
approved by the Commonwealth Scientiﬁc and Industrial Research Or-
ganizational animal health ethics committee. The WHO Collaborating
Centre for Reference and Research on Inﬂuenza provided six sera sam-
ples from three subjects collected in 2013 with likely A/California/07/
2009 (H1N1 pdm09) inﬂuenza virus infection. One serum sample was
taken at the patient's initial doctor's visit with an inﬂuenza-like illness
and a second sample was collected approximately two weeks later at
a follow-up appointment. Inﬂuenza H1N1 pdm09 virus infection was
conﬁrmed by a complement ﬁxation test (CFT) and hemagglutination
inhibition (HI) assay (Table 1). Plasma samples from11 volunteers chal-
lenged with A/Wisconsin/67/2005 (H3N2) inﬂuenza were provided
froma previously published study conducted on behalf of theUniversity
of Oxford. Initially all participants, aged 18–45, had undetectable serum
Abs to the challenge A/Wisconsin/67/2005 (H3N2) strain (HI ≤ 10).
The volunteers were infected with A/Wisconsin/67/2005 (H3N2) intra-
nasally while under quarantine. They were monitored for viral shed-
ding, disease symptoms and a HI assay was performed 36 days post-
challenge (Table 2) (Lillie et al., 2012). Healthy blood donors provided
PBMCs as a source of NK cells in some assays. The relevant human ethics
committees approved all studies.
2.2. Intravenous Immunoglobulin (IVIG)
We studied 18 IVIG preparations collected over 7 years from 2004 to
2010 as a representation of pooled IgG from thousands of healthy HIV
negative donors (Sandoglobulin, CSL Behring, Australia). The 18 IVIG
preparations were made by cold ethanol fractionation and were 96%
IgG. Stock IVIG preparations are at a concentration of 60-200 mg/ml
and prior to use all preparations were diluted to a concentration of
10 mg/ml in Fetal Calf Serum (FCS) as previously described (Jegaskanda
et al., 2014a).
2.3. Cell Lines and Viruses
The NK cell line GFP-CD16 (176V) NK-92 (Gong et al., 1994) was
used to perform some of the NK cell activation assays. The parental
cells of GFP-CD16 (176V) NK-92 are NK-92 cells from the ATCC
(CRL-2407). GFP-CD16 (176V) NK-92 cells have been transduced with
a retrovirus to express the high afﬁnity variant of CD16 (V176) in the
pBMN-IRES-EGFP vector. On these cells surface expression of CD16
(V176) correlates with GFP expression. GFP-CD16 (176V) NK-92 cells
were kindly provided by Dr. Kerry Campbell from the Institute for
Cancer Research in Philadelphia, PA.
A549 (ATCC) and CEM.NKr-CCR5 cells (NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH) were used as targets for cytotoxicity as-
says. Recombinant vaccinia viruses (rVV) were generated by homolo-
gous recombination of vaccinia infected cells with non-conjugative
plasmids expressing inﬂuenza genes into the vaccinia 7.5 k or TK
genes as previously described (Mackett et al., 1984). rVVs containing
individual HA, NP or M1 genes from inﬂuenza A/Puerto Rico/8/1934
(H1N1) were kindly provided by Drs. Jonathan Yewdell and Jack
Bennink (NIH, Bethesda, MD) and expanded by Dr. Weisan Chen
Table 2
Disease outcome, virus shedding, HI titre and percent change in Ab-dependent NK-92 activation 36 days post-infection for 11 subjects experimentally infectedwith A/Wisconsin/67/2005
(H3N2).
Subject Disease severity Virus
shed
HI titre to
A/Wisconsin/67/2005
Percent change of CD107a+ NK-92s to
H3 Wsn05 protein post-infection
Percent change CD107a+ NK-92s
to M1 protein post-infection
Percent change CD107a+ NK-92s
to NP protein post-infection
72 Moderate/severe N 80 91.2 80.3 26.5
84 Moderate/severe Y 40 21.1 0.7 2.1
87 Moderate/severe Y 80 52.8 −22.8 −0.7
100 Moderate/severe Y 160 23.1 −14.9 6.5
81 Mild Y b10 0.4 −7.8 −1.3
95 Mild Y b10 −5.7 8.8 28.9
96 Mild N 20 −6.8 −4.6 −1.4
109 Mild N 80 10.4 9.0 3.7
86 None N 320 12.4 22.7 21.3
93 None N 320 3.4 3.4 −4.3
108 None N 20 23.5 17.6 10.5
Median percent change of CD107a+ NK-92s post-infection 12.4 3.4 3.7
⁎Table adapted from previously published work by Lillie et al. (2012)
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1985).2.4. NK Cell Activation Assay
NK cell activation assays performed with inﬂuenza-infected cells as
targets and polyclonal serum does not allow for the study of responses
to individual Inﬂuenza proteins. Thus, NK cell activation was measured
by the ability of Abs bound to a plate coated with inﬂuenza proteins to
induce NK cell expression of IFNγ and CD107a as previously described
(Jegaskanda et al., 2013a, 2013b, 2013c, 2013d, 2014a, 2014b). Brieﬂy,
96-well ELISA plates (Nunc, Rochester, NY) were coated with 600 ng
of puriﬁed inﬂuenza protein (Sino Biological, Shanghai, China) over-
night at 4 °C in PBS. The wells were washed ﬁve times with PBS and
incubated with heat-inactivated (56 °C for 1 h) undiluted sera/plasma
or IVIG for 2 h at 37 °C. Plates were washed seven times with PBS and
106 peripheral blood mononuclear cells (PBMCs) or 5 × 105 puriﬁed
NK cells were added to each well. Healthy donor PBMCs were obtained
from buffy packs provided by the Australian Red Cross. PBMCswere iso-
lated by Ficoll-Paque PLUS (GE Healthcare, Madison, WI), washed with
RF10 (RPMI 1640 supplemented with 10% FCS, penicillin, streptomycin
and l-glutamine; Life Technologies, Grand Island,NY), frozen in FCS con-
taining 10% DMSO and stored in liquid nitrogen. Once thawed PBMCs
were washed twice with RF10 before addition to each well. Puriﬁed
NK cells were made from fresh PBMCs using the EasySep Human NK
Cell Enrichment Kit (Stemcell Technologies, Vancouver, Canada). Anti-
human CD107a allophycocyanin-H7 Ab (clone H4B4; BD Biosciences,
San Jose, CA), 5 μg/ml brefeldin A (SigmaAldrich) and 5 μg/mlmonensin
(Golgi Stop; BD Biosciences) were added to the cells and incubated for
5 h at 37 °C with 5% CO2. PBMCs were then incubated with 1 mM
EDTA to minimize cell adherence to the plates, anti-human CD3 PerCP
(clone SP34-2) and anti-human CD56 allophycocyanin (clone B159;
both from BD Biosciences) for 30 min at room temperature in the
dark. Cells were ﬁxed with 1% formaldehyde (Sigma Aldrich, St. Louis,
M1) for 10 min and permeabilized with FACS permeabilizing solution
2 (BD Biosciences) for 10 min. PBMCs were then incubated at room
temperature for 1 h with IFNγ AF700 (clone B27; BD Biosciences) in
the dark. Finally, cells were again ﬁxed with 1% formaldehyde and
50,000–100,000 (20,000–50,000 for puriﬁed NK cells) events were gen-
erally acquired on the LSRII ﬂow cytometer (BD Biosciences). Plasma
from inﬂuenza-naïve pigtail macaques was used as a negative control
in some NK cell activation assays. Virtually all humans are serially ex-
posed to inﬂuenza viruses from early childhood and inﬂuenza-naïve
humans are rare. We have previously shown that Ig puriﬁed from
inﬂuenza-exposed pigtail macaques can induce activation of primary
humanNK cells, whereas naïvemacaque plasma collected prior to inﬂu-
enza exposure failed to activate NK cells (Jegaskanda et al., 2013a).GFP-CD16 (176V) NK-92 cells and CD16-negative parental NK-92
cells were also used in some NK cell activation assays that required a
large number of cells. The ELISA plate coating was performed as de-
scribed above. Following PBS washing, however, an additional blocking
step was performed with PBS containing 5% Bovine serum albumin
(Sigma Aldrich, St. Louis, MI) and 0.1% Tween 20 (U-CyTech) for 2 h
at 37 °C. Once blocked, plates were washed with PBS and incubated
with heat-inactivated sera/plasma or IVIG for 2 h at 37 °C. Plates were
washed with PBS, 2 × 105 GFP-CD16 (176V) NK-92 cells were added
to each well and incubated at 37 °C with 5% CO2 for 5 h. Anti-human
CD107a allophycocyanin (clone H4A3; BD Biosciences) and 1 mM EDTA
were added to the cells for 30 min at room temperature in the dark.
GFP-CD16 (176 V) NK-92 cells were then washed twice with PBS,
ﬁxedwith 1% formaldehyde and 50,000–100,000 events were generally
acquired on the LSRII ﬂow cytometer. Analysis was performed using
FlowJo X 10.0.7r2 software (FlowJo LLC, Ashland, OR).
2.5. Dimeric Recombinant Soluble FcγRIIIa (CD16a) Binding ELISA
We recently developed a dimeric recombinant soluble FcγRIIIa
(rsFcγRIIIa) ELISA to model the need for ADCC-inducing Abs to cross
link FcγRIIIa (unpublished data;Wines et al). For the dimeric rsFcγRIIIa
binding assay, a 96-well ELISA plate was coated with 50 ng of puriﬁed
inﬂuenza protein or PBS overnight at 4 °C in PBS. The plate was washed
twice with PBST and blocked with 140 μl of PBS 1 mM EDTA 1% BSA
(PBSE/BSA) for 1 h at 37 °C. The plate was then washed twice with
PBST and 50 μl of half log plasma dilutions (1:10, 1:32, 1:100 and
1:320) in PBSE/BSA was added. Following addition of plasma dilutions,
the platewas incubated at 37 °C for 1 h. The ELISA platewaswashed ﬁve
times with PBST and 50 μl of 0.1 μg/ml rsFcγRIIIa (V176) dimer was
added to the wells then the plate was incubated for 1 h at 37 °C. Pierce
High Sensitivity HRP-Streptavidin (Thermo Fisher Scientiﬁc, Waltham,
MA) was diluted 1:10,000 in PBSE/BSA, added to all wells and the
plate was incubated at 37 °C for 1 h. The plate was washed eight times
with PBST and blotted dry. 50 μl of TMB substrate was added to each
well and the plate was developed for 4–8 min in the dark. The reaction
was stopped with 1 M HCl and the plate was read at an absorbance
of 450 nm. Intragam 5 (bioCSL, Melbourne, VIC) diluted in PBSE to
5 μg/ml was coated on all plates as a positive control and allowed for
normalisation between plates in large assays.
2.6. ADCC Killing Assay With Recombinant Vaccinia Viruses (rVVs)
Expressing Single Inﬂuenza Proteins
To study ADCC-mediated cytotoxicity, we adapted an ADCC assay
that measures LDH release from target cells as previously described
(Cox, 1999; Gooneratne et al., 2015). Brieﬂy, CEM.NKr-CCR5 cells or
A549 cells were infected with rVVs (either wild type rVV, rVV NP, rVV
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in 0.1%BSA PBS at anMOI of 10 for onehour at 37 °C. Following infection
the wells were topped up with RF10 and incubated for 8 h or 20 h at
37 °C with 5% CO2. The rVV-infected cells were then washed three
times with fresh RF10 media. The CytoTox 96 nonradioactive cytotoxic-
ity kit (Promega,Madison,WI)was utilized tomeasure lactate dehydro-
genase (LDH) release from the cytoplasm of cells killed by ADCC. The
rVV-infected cells were the targets with freshly isolated healthy donor
PBMCs or NK-92 cells as the effectors. Spontaneous release of LDH
from target and effector cells was determined by incubation of each
cell type alone. Maximum LDH release from target cells was determined
by addition of lysis buffer to target cells during the 4 h incubation at
37 °C. Background levels of LDH in RF10 media were determined by
media only control wells. In assays were CEMswere used as targets, ex-
perimental wells contained 2 × 104 rVV-infected CEM cells combined
with 5 × 105 or 2.5 × 105 PBMCs in an effector to target ratio of 25:1
or 12.5:1. When A549 cells were used as targets, experimental wells
contained 3 × 104 rVV-infected A549 cells combined with 7.5 × 105
PBMCs in an effector to target ratio of 25:1. In assays where NK-92
cells were used as effectors, experimental wells contained 2 × 104
rVV-infected target cells combined with 1 × 105 or 2 × 104 NK-92s
in an effector to target ratio of 5:1 or 1:1 respectively. To measure
inﬂuenza-speciﬁc ADCC, IgG was puriﬁed from a healthy inﬂuenza-
exposed adult, with known M1 and NP-speciﬁc NK cell activating
Abs and who was not immunised against VV, using the Protein G HP
Multitrap and Antibody Buffer Kit (both GE Healthcare, UK) according
to the manufacturer's instructions. Puriﬁed IgG was added to the ex-
perimental wells giving ﬁnal concentrations of 50 μg/ml, 5 μg/ml and
0.5 μg/ml. Killing of infected target cells by effectors in the absence of
Ab was measured by adding PBS to wells containing both the effectors
and targets (no Ab control). We assessed ADCC to target cells infected
with ﬁve different rVVs, therefore experimental and control conditions
were prepared separately for target cells infected with each virus. Addi-
tionally all control and all experimental conditions were set-up in trip-
licate. Once all reagents were added to the appropriate wells the plates
were spun at 250 ×g for four minutes then incubated at 37 °C 5% CO2
for 4 h. Following incubation, the plates were again spun at 250 ×g
for 4 min then 50 μl of supernatant was transferred to another ﬂat-
bottom 96-well plate. 50 μl of substrate solution was added to wells
containing supernatant and plateswere incubated at room temperature
in the dark for 30min. The reaction was then stopped with 50 μl of stop
solution and the absorbancewas recorded at 490 nm. The optical densi-
ty of the media only control was subtracted from all other values. The
following formula was then used to calculate percentage cytotoxicity
for all experimental conditions % cytotoxicity = [(experimental −
effector spontaneous− target spontaneous) / (maximum LDH− target
spontaneous)].
2.7. Statistical Analysis
Statistical analysis was performed with Prism GraphPad version
5.0d (GraphPad Software, San Diego, CA). Data presented in Fig. 1b
and c were analysed by Mann Whitney U test to compare NK cell acti-
vation by plasma from inﬂuenza-exposed humans to NK cell activation
by plasma from inﬂuenza-naïve macaques. A Friedman test was used
to determine if there was a signiﬁcant overall difference in NK cell ac-
tivation for the same set of samples (14 healthy donors in Fig. 1b, c; 18
IVIG preparations in Fig. 4a, b) exposed to multiple conditions (HA vs
M1 vs NP vs gp140). A Wilcoxon matched pairs signed-rank test was
used, alone or in concert with a Friedman test, to pinpoint whether
there was a signiﬁcant difference in NK cell activation for paired sam-
ples exposed to two separate conditions (inﬂuenza protein vs irrele-
vant HIV-1 protein for Figs. 1b, c and 4a, b; pre- vs post-infection for
Figs. 6a–c and 7). The Wilcoxon matched pairs signed-rank test was
sometimes performed multiple times on the same data set therefore
a Bonferroni correction was used to correct the p value for multiplecomparisons (Fig. 1b, c; Fig. 4a, b). A nonparametric Spearmen correla-
tion was performed to determine whether there was a statistically
signiﬁcant correlation between two data sets (Fig. 2c, e; Fig. 3b, c;
Fig. 5c; Fig. 6d).
2.8. Role of the Funding Source
Funding was generously provided by the Australian National Health
and Medical Research Council (NHMRC; grants 628331, 023294, and
510488 to Stephen J Kent). The funding source had no role in study de-
sign, data collection and interpretation, or the decision to submit the
work for publication.
3. Results
3.1. NK Cell Activating Antibodies to M1 and NP are Common in
Inﬂuenza-exposed Healthy Adults
Inﬂuenza NP and M1 proteins are common targets for T cell immu-
nity butwhether they also elicit functionally important Abs that activate
NK cells has not been well studied. Plasma from 14 healthy inﬂuenza-
exposed human adults and four inﬂuenza-naïve pigtail macaques
were ﬁrst tested for NK cell activating Abs to M1 from the A/Puerto
Rico/8/1934 (H1N1) inﬂuenza virus and NP from the H1N1 pdm09 in-
ﬂuenza virus. The ability of plasma Abs to bind immobilized inﬂuenza
proteins and activate primary NK cells to express the antiviral cytokine
IFNγ and degranulation marker CD107a was studied by ﬂow cytometry
(Fig. 1a).
Degranulation of NK cells would likely be more efﬁcient in the pres-
ence of inﬂuenza-infected target cells, but for the purpose of studying
NK cell activation by polyclonal Abs to individual inﬂuenza proteins in
human sera or pooled IgG immobilized inﬂuenza proteins were used.
Two additional inﬂuenza HA proteins from recently circulating strains,
the HA of the A/Perth/19/2009 (H3N2) virus (H3 Perth09) and the
HA of the H1N1 pdm09 virus (H1pdm09), were also tested for Ab-
dependentNK cell activation (Fig. 1b, c) since HA is awell-characterized
target of ADCC (Jegaskanda et al., 2013a, 2013b, 2013c, 2013d, 2014a,
2014b). An irrelevant viral Ag, HIV-1 gp140, was used to coat negative
control wells since all healthy donors were HIV negative. Primary NK
cells from different human donors commonly demonstrate skewing to-
wards either IFNγ or CD107a expression, and the plasma or IgG samples
tested can further bias the NK cell activation proﬁle. IVIG (Fig. 1a) ap-
peared to elicit less CD107a expression in the primary NK cells we
used compared to the responses observed in healthy donor plasma
(Fig. 1c). This is not surprising as we have previously shown that isola-
tion of IgG from sera decreased CD107a expression in primary NK cells
suggesting that soluble factors in plasma or sera, other than IgG, can
alter NK cell activation proﬁles (Wren et al., 2012).
Plasma from inﬂuenza-exposed human adults induced substantial
expression of IFNγ and CD107a in primary NK cells in response to
both internal inﬂuenza proteins M1 and NP (Fig. 1b, c). Following incu-
bationwith healthy donor plasma andM1, themedian percentage of NK
cell activationwas 4.46% for IFNγ+ and 0.84% for CD107a+ compared to
low levels of NK cell activation induced by inﬂuenza infection-naïve
macaque plasma (median IFNγ+: 0.6% and median CD107a+: 0.37%,
p b 0.001). Similarly, the proportion of NK cells expressing IFNγ and
CD107a in response to anti-NP Abs was signiﬁcantly greater in the
presence of human donor plasma than in the presence naïve macaque
plasma (median IFNγ+: human plasma 2.72% vs macaque plasma
0.11%, p b 0.001; median CD107a+: human plasma 1.58% vs macaque
plasma 0.34%, p b 0.001). Inﬂuenza-exposed human plasma also led
to more robust NK cell activation when PBMCs were stimulated with
inﬂuenza Ags compared to HIV-1 gp140 stimulated cells (Fig. 1b, c).
The gp140-coated wells had very low levels of NK cell activation in
the presence of healthy donor plasma (median IFNγ+: 0.13% andmedi-
an CD107a+: 0.43%) conﬁrming that activation was inﬂuenza speciﬁc
Fig. 1.M1- and NP-speciﬁc primary NK cell activation in healthy inﬂuenza-exposed adults. a) Lymphocytes were gated on by size and granularity (FSC-A vs SSC-A) ensuring single
cells (FSC-A vs FSC-H). CD3− CD56+ dim primary NK cells were selected for analysis using IFNγ and CD107a as activation markers. PBMCs were incubated with inﬂuenza protein
(600 ng/well) in the absence of IVIG from inﬂuenza-exposed adults, irrelevant viral protein gp140 (600 ng/well) with IVIG from inﬂuenza-exposed adults and inﬂuenza proteins (M1
and NP) with IVIG from inﬂuenza-exposed adults. Primary NK cell activation with plasma from 14 healthy adults (Flu+) and four inﬂuenza-naïve pigtail macaques (Flu−) is shown
by IFNγ (b) and CD107a (c) expression to HA of A/California/04/2009 (H1pdm09), HA of A/Perth/19/2009 (H3Perth09), M1 of A/Puerto Rico/8/1934 (M1), NP of A/California/07/2009
(NP) and irrelevant viral protein gp140. Values are unsubtracted with gp140 background shown for all samples. For each inﬂuenza protein tested Flu+ and Flu− groups were
compared with a Mann Whitney U test where p b 0.05 was considered signiﬁcant. A Friedman test followed by a Wilcoxon matched pairs signed-rank test with a Bonferroni
correction for multiple comparisons was used to compare the Flu + group incubated with M1 and NP to the Flu + group incubated with irrelevant protein gp140, a corrected p value
of b0.0125 considered signiﬁcant. *** = p b 0.001.
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which there has been no previous exposure. Unsurprisingly, HA
proteins from both H1N1 pdm09 virus and A/Perth/19/2009 (H3N2)
virus elicited high levels of NK cell activation (H1pdm09 median
IFNγ+: 5.24% and CD107a+: 1.55%; H3 Perth09 median IFNγ+: 12.01%
and CD107a+: 2.71%). For both HAs, the 14 healthy donor plasma sam-
ples had detectable NK cell activation (at least three times the percent-
age of IFNγ+ NK cells in gp140 coated wells with plasma). Remarkably
M1 and NP also showed above background NK cell activation for all
healthy donors tested. Thus, NK cell activating Abs speciﬁc for inﬂuenza
M1 and NP are present in the plasma of healthy adults. To show that in-
ﬂuenza proteins opsonised by polyclonal Abs are capable of activating
NK cells without the involvement of other cells types we puriﬁedprimary NK cells and performed an NK cell activation assay. When
healthy donor plasma was added to surface (H1pdm09 and H3
Perth09) or internal (M1 and NP) inﬂuenza proteins, puriﬁed NK cells
exhibited robust expression of IFNγ and CD107a (Supplementary
Fig. 1) suggesting a direct mechanism of NK cell activation.
Primary NK cells in PBMCs exhibit variable levels of responsiveness
to NK cell activating Abs over time and between donors. To conﬁrm
the above results we utilized an NK cell line, GFP-CD16 (V176) NK-92,
as an alternative means for measuring NK cell activation. In addition,
the larger numbers of NK-92 cells available allowed us to titrate M1
andNP-speciﬁc NK cell activatingAbs in our cohort of 14 healthy donors
(Fig. 2b, d). NK-92 activation was assessed by surface expression of
CD107a (Fig. 2a). Ab-induced NK-92 activation to M1 protein was
Fig. 2. Titration of M1- and NP-speciﬁc NK activating Abs in healthy adults with NK-92 cells and correlation with primary NK cells. a) NK-92 cells were gated on by size and granularity
(FSC-Avs SSC-A) ensuring single cells. CD16-GFP+cellswere selected for analysis using CD107a as an activationmarker. NK-92 cellswere incubatedwith inﬂuenza protein (600 ng/well)
in the absence of IVIG from inﬂuenza-exposed adults, irrelevant viral protein gp140 (600 ng/well)with IVIG from inﬂuenza-exposed adults and inﬂuenza proteins (M1 and NP)with IVIG
from inﬂuenza-exposed adults. 14 healthy donor plasma samples previously screened for primary NK cell activation in the presence of inﬂuenza proteins (Fig. 1b, c) were titrated for
NK cell activating Abs to M1 (b) in a series of 2-fold plasma dilutions and NP (d) in a series of 4-fold plasma dilutions. All values were background subtracted with wells containing
plasma and the irrelevant HIV-1 protein gp140. Correlations between primary NK cell activation (percentage of NK cells expressing IFNγ) with undiluted plasma and NK-92 activation
(percentage of NK-92 cells expressing CD107a) with a 1:40 plasma dilution are shown for M1 (c) and NP (e). Spearman correlation was used to determine correlation between
primary NK and NK-92 cell activation where p b 0.05 was considered signiﬁcant.
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mary NK cell activation with undiluted plasma correlated with NK-92
activation for all plasma dilutions between 1:10 and 1:1280 for the
M1 protein (correlation for 1:40 dilution shown in Fig. 2c). All plasma
samples also had detectable NK-92 activation to NP at a 1:10 dilution,
but a slight prozone effect was observed for half of the plasma samples
(Fig. 2d). We speculate that high levels of NP-speciﬁc NK cell activatingAbs may be inhibitory to NK-92 cells, yet there was still a signiﬁcant
correlation between primary NK cell activation with undiluted plasma
and NK-92 activation for plasma dilutions between 1:10 and 1:10,240
(correlation for 1:40 dilution shown in Fig. 2e). IFNγ was the marker
of primary NK cell activation used for the correlations shown in Fig. 2,
however these analyses were also performed with percentages of pri-
mary NK cells expressing CD107a and yielded similar results (data not
Fig. 3. NP and M1 opsonised with Abs from healthy inﬂuenza-exposed adults bind dimeric
rsFcγRIIIa. a) A subset of 9 healthy human donors (closed circle) and one inﬂuenza-naïve
macaque (open circle) previously screened for NK cell activating Abs to M1 and NP (Figs. 1,
2) were tested for dimeric rsFcγRIIIa binding to Ab opsonised M1 and NP using a novel
ELISA. Three half-log plasma dilutions starting at 1:10 were screened for each donor. All
normalised OD values were subtracted with a no antigen control well, containing plasma
but no inﬂuenza protein. Correlations between primary NK cell activation (percentage of
NK cells expressing IFNγ) and dimeric rsFcγRIIIa binding with a plasma dilution of 1:10 for
M1 (b) and 1:320 for NP (c) are shown. All percentages of primary NK cells expressing
IFNγ are background subtracted with wells containing plasma and the irrelevant HIV-1
protein gp140. Spearman correlation was used to determine correlation between primary
NK cell activation and dimeric rsFcγRIIIa binding where p b 0.05 was considered signiﬁcant.
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through FcγRIIIa (CD16a) we also performed an NK cell activation
assaywith the parental NK-92 cell line, which does not express FcγRIIIa.
These results showed that parental NK-92 cells could not be activated in
the presence of pooled human IgG and internal inﬂuenza proteins,
while NK-92 cells transduced with FcγRIIIa (CD16a) demonstrated
robust activation by CD107a expression (Supplementary Fig. 2). The
strong correlation of Ab-mediated NK-92 cell activation with primary
NK cell activation, as well as the FcγRIIIa dependence of their CD107a
expression, suggests that NK-92 cells are a reasonablemodel of primary
NK cell activation when studying inﬂuenza-speciﬁc Abs in humans.
3.2. NP andM1OpsonisedWith Antibodies FromHealthy Inﬂuenza-exposed
Adults Bind Dimeric rsFcγRIIIa
ADCC Abs bind targets via their Fab regions and subsequently their
Fc regions bind and crosslink FcγRIIIa to activate NK cells. A recently de-
scribed dimeric rsFcγRIIIa binding ELISA (unpublished data; Wines
et al.) was used to examine a subset of nine healthy donors and one
inﬂuenza-naïve pigtail macaque. At a 1:10 plasma dilution all nine
healthy inﬂuenza-exposed adults had detectable M1 and NP-speciﬁc
Abs which reacted with Ag and bound dimeric rsFcγRIIIa (Fig. 3a).
Detectable receptor binding was deﬁned as an OD value twice that of
the corresponding control well with plasma but no inﬂuenza protein.
The inﬂuenza-naïve macaque did not demonstrate detectable dimeric
rsFcγRIIIa binding to Ab opsonised to M1 or NP at any plasma dilution
tested. Median dimeric rsFcγRIIIa (normalised OD) for the nine human
donors at a 1:10 plasma dilution was 0.29 for M1-speciﬁc Abs and
1.06 for NP-speciﬁc Abs. Abs opsonisingM1 appeared to titre out rapidly
for dimeric rsFcγRIIIa with all but one donor falling below the threshold
of detection by the 1:320 plasma dilution. In contrast, most donors
(7 out of 9) had Abs that opsonised NP with detectable dimeric
rsFcγRIIIa binding at a 1:320 plasma dilution (Fig. 3a).
The dimeric rsFcγRIIIa binding activity of M1 andNP opsonisedwith
Abs correlated with primary NK cell activation. For the M1 protein,
opsonisation with plasma diluted at 1:10 (Fig. 3b; r = 0.89, p =
0.001), 1:32 (data not shown; r = 0.87, p = 0.002) and 1:100 (data
not shown; r = 0.84, p = 0.004) resulted in dimeric rsFcγRIIIa binding
activity that correlated signiﬁcantlywith primaryNK cell activation. At a
1:320dilutionAb opsonisation ofM1appeared to have decreased below
the threshold of detectable dimeric rsFcγRIIIa binding (data not shown;
r = 0.47, p = 0.17). Signiﬁcant correlations between primary NK cell
activation and dimeric rsFcγRIIIa binding with plasma dilutions of
1:32 (data not shown; r = 0.67, p = 0.04), 1:100 (data not shown;
r = 0.72, p = 0.02) and 1:320 (Fig. 3c; r = 0.72, p = 0.02) were also
demonstrated for NP. At the 1:10 plasma dilution high levels of anti-
NP Abs gave uniform, elevated dimeric rsFcγRIIIa binding across all
healthy inﬂuenza-exposed donors and did not show a statistically
signiﬁcant correlation (data not shown; r = 0.48, p = 0.17). This high-
lights the importance of optimizing plasma dilutions for the dimeric
rsFcγRIIIa binding ELISA based on the cohort and the Ag being tested.
Collectively these results suggest that Abs capable of opsonising M1
and NP to form complexes with dimeric rsFcγRIIIa are present in most
healthy donors and that this rsFcγRIIIa binding activity correlates with
NK cell activation.
3.3. NK Cell Activation by Antibodies to M1 and NP in IVIG Samples
To further investigate the levels of NK cell activating Abs to internal
inﬂuenza proteins across large numbers of subjects, the activation of
primary NK and NK-92 cells was examined for 18 IVIG samples. Eight
of the IVIG preparations were made with samples donated prior to the
2009 inﬂuenza pandemic (pre-2009) and ten were made with samples
collected after the 2009 pandemic (post-2009). All these commercial
IVIGs were prepared by pooling IgG samples from thousands of HIV-
negative donors, allowing average inﬂuenza-speciﬁc NK cell activating
Fig. 4. Inﬂuenza-speciﬁc NK cell activation by IVIG preparations and titration of H1pdm09, M1 and NP NK cell activating Abs in ﬁve IVIG samples. 18 IVIG preparations (10 mg/ml) were
tested for primary NK cell (a) and NK-92 cell (b) activation to inﬂuenza proteins H1pdm09, M1 and NP aswell as the irrelevant HIV-1 protein gp140. Values are unsubtractedwith gp140
background shown for all samples. A Friedman test followed by a Wilcoxon matched pairs signed-rank test with a Bonferroni correction for multiple comparisons was used to compare
inﬂuenza-speciﬁc NK activation by IVIGs to activation by gp140, a corrected p value of b0.0167 considered signiﬁcant. Titrations of NK cell activating Abs to H1pdm09 (c), M1 (d) and NP
(e)were performed in a series of 2-fold dilutions for ﬁve IVIG samples two prepared pre-2009 (broken line, open symbol) and three prepared post-2009 (solid line, closed symbol). For all
titrations (c–e) values were background subtracted with wells containing IVIG and gp140. *** = p b 0.001.
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proteins demonstrated robust activation of both primary NK cells
(Fig. 4a) and NK-92 cells (Fig. 4b). The control HIV-1 gp140 protein in-
duced only background levels of IVIG-mediated NK cell activation. The
internal inﬂuenza protein M1 demonstrated robust activation of prima-
ry NK cells (median IFNγ+: M1 14.6% vs gp140 0.48%, p b 0.0001)
and NK-92 cells (median CD107a+: M1 PR8 36.8% vs gp140 0.70%,
p b 0.0001). NP also elicited signiﬁcant levels of Ab-mediated activation
of NK cells (median IFNγ+: NP 5.95% vs gp140 0.48%, p b 0.0001) and
NK-92 cells (median CD107a+: NP 12.7% vs gp140 0.70%, p b 0.0001).
The levels of NK cell activation clustered quite closely across the
18 IVIG samples for each inﬂuenza Ag tested (Fig. 4a, b), this is not sur-
prising due to the large number of donors used to generate each IVIG
preparation. NK cell activation detected with IVIG demonstrates that
M1 and NP-speciﬁc NK cell activating Abs are present in the population
as a whole, which is consistent with what we observed in 14 healthy
adult donors. There was no signiﬁcant difference in primary NK cell or
NK-92 activation between pre-2009 and post-2009 samples for the
H1pdm09 protein as previously described (Jegaskanda et al., 2014a),
M1 or NP (data not shown), suggesting the advent of the 2009 pandem-
ic did not have a major impact on population level ADCC responses to
these inﬂuenza proteins.
The portion of activated NK cells at a single high concentration of
IVIG (10 mg/ml) may not reﬂect the amount of NK cell activating Abs
present. To compare the quantity of H1pdm09, M1 and NP-responsive
NK cell activating Abs in the population ﬁve IVIG samples (two pre-
2009 and three post-2009)were titrated in a series of two-fold dilutions
with NK-92 cells. All ﬁve IVIG preparations showed similar titration
patterns for each inﬂuenza protein (Fig. 4c–e). NK cell activating Abs
to HA, M1 and NP appeared to titre out at similar IVIG concentrations
despite varying levels of NK-92 activation at the initial concentration
of 10 mg/ml.3.4. NK Cell Activation by Antibodies in Naturally Inﬂuenza-infected Adults
The above studies reﬂect NK cell activating Ab levels from individ-
uals with unknown histories of inﬂuenza infections. To determine the
impact of symptomatic inﬂuenza infection on the function and levels
of human NK cell activating Abs, sequential sera samples ranging from
pre to post-seroconversion were obtained from three adults and tested
for NK cell activating Abs to HA,M1 andNP.We deﬁned the ﬁrst sample
obtained from the subjects upon presentation with symptomatic illness
as the “pre-seroconversion sample” although the acquisition of infection
would have been prior to this time. The post-seroconversion samples
were taken 12–17 days later. Post-seroconversion sera from all patients
demonstrated increased HI titre and complement ﬁxation to HA of the
H1N1 pdm09 strain (Table 1). Titrations of patient sera were performed
to compare themagnitude of NK cell activation and the levels of NK cell
activating Abs between pre and post-seroconversion samples. At a 1:80
serum dilution all three patients showed a rise in NK-92 activation to
the H1pdm09 protein post-seroconversion (post 3.5–14% CD107a+ vs
pre 1–3% CD107a+). Patients 1 and 3 also showed a substantial rise in
NK-92 activation to M1 protein in post-seroconversion sera (34–36%
CD107a+) compared to pre-seroconversion samples (5–14% CD107a+,
Fig. 5a). Only patient 2 showed some increase in NK-92 activation to
NP after seroconversion at a 1:80 dilution (Fig. 5a). Over most dilutions,
there was higher NK cell activation in the post-seroconversion sample
compared to the pre-seroconversion sample for both M1 and NP inter-
nal proteins as well as the H1pdm09 protein. Two of the three patients
demonstrated a higher endpoint titre of NK cell activating Abs to HA
post-seroconversion (patient 1: post 160 vs pre b80; patient 2: post
80 vs pre b80), whereas patient 3 showed no increase in endpoint
titre post-seroconversion. Interestingly, the endpoint titres of M1 and
NP-speciﬁc NK cell activating Abs remained constant pre and post-
seroconversion for patients 1 and 3 (M1: 1280 and NP: 5120) and
Fig. 5. NK-92 activation by pre- and post-seroconversion sera samples from three naturally inﬂuenza-infected patients. a) A titration of NK-92 cell activating Abs, measured
by percentage of CD107a+ cells, was performed with sera from subjects naturally infected with a suspected A/California/07/2009 (H1N1)-like inﬂuenza virus. NK cell activating
Abs to inﬂuenza H1pdm09, M1 and NP were titrated in pre (broken line) and post-seroconversion (solid line) sera by 2-fold serial dilutions starting at a 1:80 dilution. All
values were background subtracted with wells containing patient sera and gp140. b) Endpoint titres of NK cell activating Abs to H1pdm09 (closed black circles), M1 (open
squares) and NP (grey triangles) are shown in pre- and post-seroconversion sera for the three subjects. Endpoint titres of NK cell activating Abs were deﬁned as the last serum
dilution before the percentage of NK-92 cells expressing CD107a fell below the threshold of three times background (calculated with wells containing sera and gp140).
c) Correlation of NK cell activation (by CD107a expression) at a 1:80 serum dilution to endpoint titre of NK cell activating Abs. The percentage of CD107a+ NK-92 cells and the
endpoint titres of NK cell activating Abs are depicted for all inﬂuenza proteins tested (H1pdm09, M1 and NP) with pre- and post-seroconversion sera from the three subjects
naturally infected with inﬂuenza virus. Spearman correlation was used to compare NK-92 activation and endpoint titre of NK cell activating Abs, where p b 0.05 was
considered signiﬁcant.
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10,240; NP: post 5120 vs pre N20,480, Fig. 5b). This suggests that al-
though the potency of the Abs' ability to activate NK cells was enhanced,
the amount of NK cell activating Abs was not increased. A strong corre-
lation between endpoint titre of NK cell activating Abs and NK cell acti-
vation at a single dilution was observed when the three inﬂuenza Ags
tested (HA, M1 and NP) were analysed together for pre and post-
seroconversion sera samples (Fig. 5c). This suggests that despite the
lack of an increase in endpoint titre to M1 and NP post-seroconversion,
there appeared to be signiﬁcant relationship between NK-activating
Ab levels and the degree of NK cell activation for these subjectswith nat-
urally acquired inﬂuenza infection.
3.5. NK-92 Activation by Antibodies in Experimentally Inﬂuenza-infected
Adults
The precise timing of the inﬂuenza infection in the above study
wasnot known,with the initial sample taken atﬁrstmedical contact fol-
lowing inﬂuenza-like symptoms. To study anti-inﬂuenza NK cell acti-
vating Abs in a more controlled setting we assayed plasma samples
from an experimental inﬂuenza infection where the pre-infection sam-
plewas taken prior to infection. The subjects studiedwere a cohort of 11
healthy volunteers infected with the inﬂuenza A/Wisconsin/67/2005
(H3N2) virus as controls for a previously published T cell based inﬂuen-
za vaccine study. The clinical and serological outcome varied widelyFig. 6. Inﬂuenza-speciﬁc Ab-dependent NK-92 activation in subjects experimentally infected w
incubation with H3 Wsn05 (a), M1 (b) and NP (c) was compared for pre and post (36 days) i
A/Wisconsin/67/2005 (H3N2) inﬂuenza virus. Black lines (circles) represent individuals that d
disease and broken lines (triangles) are individuals that did not demonstrate any disease sy
gp140. Wilcoxon matched pairs signed-rank test was used to test for signiﬁcant differen
signiﬁcant. * = p b 0.05, ns = not signiﬁcant. d) Correlation of HI titre to A/Wisconsin/67/20
samples. Spearman correlation was used to compare HI titre and NK-92 activation where p b 0among the volunteers (Lillie et al., 2012). Most but not all individuals
(7 of 11) seroconverted to the challenge strain (HI N 40) at 36 days
post-infection, but only ﬁve participants had detectable virus shedding
(Table 2). Volunteers were seronegative (HI b 10) to the HA of the
A/Wisconsin/67/2005 (H3N2) virus (H3 Wsn05) prior to infection,
yet all pre-infection samples gave detectable baseline Ab-dependant
NK-92 activation (7–26.7% CD107a+) to the challenge HA protein
(Fig. 6a). This is consistent with our prior work showing signiﬁcant
cross-reactive HA-speciﬁc NK cell activation in the absence of HI Abs
(Jegaskanda et al., 2013a). The conserved internal proteins M1 and NP
also elicited detectable NK-92 activation in all donors prior to the exper-
imental inﬂuenza infection (M1: 9.2%–49.1% CD107a+; NP: 18.7–30%
CD107a+) (Fig. 6b, c), consistent with the experiments above on
healthy adults. NK-92 activation to the control HIV-1 gp140 protein
was negligible. Pre-infection levels of NK cell activating Abs to the HA
of the infecting virus and M1 varied substantially between individuals
however no clear relationship between baseline NK-92 activation and
disease severity, viral shedding or seroconversion was apparent in this
small cohort.
Across all 11 subjects, there was a signiﬁcant rise in Ab-dependent
NK-92 activation to the HA protein of the challenge virus between
pre- and post-infection samples (p = 0.0137, Fig. 6a) with a median
percent change of 12.4% (Table 2). No signiﬁcant difference was ob-
served in NK-92 activation to M1 or NP between the pre- and post-
infection samples (Fig. 6b, c), with median percent changes of 3.4%ith inﬂuenza and correlation with NAbs. The percentage of CD107a+ NK-92 cells following
nfection plasma samples at a 1:20 dilution from 11 subjects experimentally infected with
eveloped moderate/severe disease, grey lines (squares) depict subjects who showed mild
mptoms. All values were background subtracted with wells containing patient sera and
ces between pre- and post-infection plasma samples where p b 0.05 was considered
05 (H3N2) and percentage of NK-92 cells expressing CD107a for post-infection plasma
.05 was considered signiﬁcant.
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moderate/severe illness showed increased NK-92 activation to the HA
of the infecting virus post-infection however, this pattern was not ob-
served for M1 or NP (shown in black lines in Fig. 6a–c). Full titrations
of pre- and post-infection samples to HA, M1 and NP were not per-
formed with the NK-92 activation assay for the 11 experimentally
infected subjects, although the levels of NK cell activation at the 1:20 di-
lution studied correlated with endpoint titrations using the FcγRIIIa
dimer binding assay above (data not shown). A signiﬁcant correlation
was observed between HI titre and NK-92 activation to the HA of
the challenge virus in plasma samples taken 36 days post-infection
(p = 0.01, r = 0.74), suggesting that infection with the A/Wisconsin/
67/2005 (H3N2) virus is generating both HA-speciﬁc neutralising and
NK cell activating Abs (Fig. 6d).
The four volunteers who developed moderate/severe disease and
demonstrated greater NK-92 activation post-infection were examined
for breadth of ADCC response to heterologous HAs. Following infection,
all four individuals showed increased NK-92 activation to two heterolo-
gous H3 Ags tested (from the non-circulating X-31 virus and from the
recently circulating A/Perth/19/2009 virus, Fig. 7). Two of the four indi-
viduals also showed increased ADCC response to the heterosubtypic
HA of the H1N1 pdm09 virus (Fig. 7). This indicates that the NK cell ac-
tivating Abs generated following symptomatic human inﬂuenza infec-
tion can recognize antigenically diverse, homosubtypic HAs and in
some cases the HAs from heterosubtypic inﬂuenza viruses.
3.6. ADCC Mediated Killing of Target Cells Expressing HA but Not M1 or NP
Although we found strong evidence that NP and M1-speciﬁc Abs
were able to opsonise these Ags, bind dimeric rsFcγRIIIa and mediate
NK cell activation, evaluating whether these Abs are able to recognize
inﬂuenza-infected cells is difﬁcult. Immune plasma contains Abs of
different speciﬁcities (e.g. HA and NA) to which ADCC of inﬂuenza-
infected will be directed (Jegaskanda et al., 2013a, 2013b, 2013c,
2013d, 2014a). As a surrogate for inﬂuenza-infected cells we infected
target cells with recombinant vaccinia viruses exclusively expressing
either HA, NP or M1 Ags. Effector cells mediated robust Ab-dependent
killing of CEM cells (Fig. 8a, c) and A549 cells (Fig. 8b) infected with
the rVV expressing inﬂuenza HA in the presence of healthy adult IgG
in all conditions tested. Low levels of ADCC were observed against
CEM (Fig. 8a, c) and A549 cells (Fig. 8b) infected with the control rVV-Fig. 7. Breadth of NK cell activating Abs to homosubtypic and heterosubtypic HA proteins
in experimentally inﬂuenza-infected subjects with moderate/severe disease. NK-92
activation following stimulation with H3 Wsn05 (unbroken black line, closed circle), H3
X-31 (broken grey line, open square), H3 Perth09 (unbroken grey line, open circle) and
H1pdm09 (broken black line, open diamond) was compared for pre and post (36 days)
infection plasma samples at a 1:20 dilution from four subjects that demonstrated
moderate/severe disease following A/Wisconsin/67/2005 (H3N2) infection. All values
were background subtracted with wells containing patient sera and gp140. Wilcoxon
matched pairs signed- rank test was used to test for signiﬁcant differences between pre-
and post-infection plasma samples where p b 0.05 was considered signiﬁcant. *** =
p b 0.001.
Fig. 8. ADCC mediated killing of targets cells infected with rVVs expressing individual
inﬂuenza proteins. a) Percent cytotoxicity (measured by LDH release) of rVV infected
CEM T-cell targets by PBMC effectors in the presence of 50 μg/ml, 5 μg/ml, 0.5 μg/ml or
0 μg/ml IgG from a healthy inﬂuenza-exposed adult. Effector PBMCs were added to
targets 20 hour post-infection (hpi) with rVV at an effector to target ratio of 25:1 (solid
lines, closed symbols) or 12.5:1 (broken lines, open symbols). b) Percent cytotoxicity of
rVV infected lung epithelial A549 targets by effector PBMCs in the presence of healthy
inﬂuenza-exposed donor IgG at concentrations of 50 μg/ml, 5 μg/ml, 0.5 μg/ml or 0 μg/ml.
PBMC effectors were added to targets 20 hpi with rVV at an effector to target ratio of
25:1. c) Percent cytotoxicity of rVV infected CEM T-cell targets by NK-92 effector cells in
the presence of healthy inﬂuenza-exposed donor IgG at 50 μg/ml, 5 μg/ml, 0.5 μg/ml or
0 μg/ml. Effector NK-92 cells were added to targets 8 hpi with rVV at effector to target
ratios of 5:1 (solid lines, closed symbols) and 1:1 (broken lines, open symbols).wt particularly at the highest concentration of IgG (50 μg/ml). However
even at an IgG concentration of 50 μg/ml, ADCCmediated killing of cells
infected with rVV-HA was still 3 to 4-fold greater than that observed
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inﬂuenza NP and M1 (Fig. 8a–c) did not show enhanced cytotoxicity
compared to cells infected with rVV-wt.
To establish that internal inﬂuenza proteins were present on the
surface of cells in the rVV infection system, we infected CEM cells with
rVV-NP or rVV-wt and surface stained with an anti-NP Ab conjugated
to FITC (Abcam, Cambridge, UK). Surface NP expression was detectable
at 5 hours post-infection (hpi) and peaked at 8 hpi with approxi-
mately 25% of unpermeabilized CEM cells showing surface NP by ﬂow
cytometry (Supplementary Fig. 3). At later time points of 24 hpi and
30 hpi with rVV-NP, surface NP declined to 6–11% of cells (Supplemen-
tary Fig. 3). In contrast, total surface and intracellular NP, measured in
permeabilized rVV-NP infected CEM cells, increased between 5 hpi
and 24 hpi with rVV-NP (Supplementary Fig. 3) showing a disparity be-
tween surface NP and total cellular NP in rVV-NP infected cells. There
was no detectable surface NP on uninfected cells or CEM cells infected
with rVV-wt (Supplementary Fig. 3). We then performed an ADCC
killing assay using NK-92 effectors and CEM targets infected with
rVV-wt, rVV-HA or rVV-NP at 8 hpi, which was the peak of surface NP
detection by ﬂow cytometry. At 8 hpi, rVV-HA infected cells elicited
strong Ab-dependent killing by NK-92s (100% cytotoxicity) but consis-
tent with previous assays at 20 h post-infection, ADCC was not in-
creased with rVV-NP infected target cells (Fig. 8c). In an rVV infection
model, it appears that viruses expressing inﬂuenza HA alone, but not
those expressing internal inﬂuenza proteins NP or M1, can mediate
ADCC of infected target cells.
4. Discussion
Highly conserved inﬂuenza proteins have the potential to generate
cross protective immunity and may provide the basis for a universal
vaccine against inﬂuenza. It has long been known that inﬂuenza-
exposed humans have Abs to NP (Ennis et al., 1982; Sukeno et al.,
1979; Yamane et al., 1981), yet the functional consequences of humoral
immunity to internal inﬂuenza Ags remain largely uncharacterised. In
this study we have shown for the ﬁrst time that individual and pooled
human sera has opsonising Abs to internal inﬂuenza proteins capable
of binding dimeric rsFcγRIIIa and activating NK cells.
Humans have been serially exposed to different inﬂuenza viruses
from early childhood resulting in detectable baseline levels of
inﬂuenza-speciﬁc ADCC Abs in the absence of NAbs (Terajima et al.,
2015), but the impact of recent inﬂuenza infection on Ab-mediated
humanNK cell responses had not been previously explored. Acute inﬂu-
enza infection has been shown to decrease absolute numbers of periph-
eral blood NK cells and lower plasma levels of inﬂammatory cytokines
(Jost et al., 2011). Inactivated inﬂuenza virions and HA can also inhibit
primary NK cell activity in vitro (Mao et al., 2010). A limitation of this
study was that PBMCs from the inﬂuenza-infected donors were not
available, so NK cell dysfunction resulting from the inﬂuenza infections
could not be assessed. Future studies could concomitantly study the re-
sponse of autologous NK cells to functional inﬂuenza-speciﬁc Abs. We
found that plasma from naturally and laboratory inﬂuenza-infected
adults showed increased Ab-mediated NK cell activation to the HA pro-
tein of the infecting strain. The experimentally infected volunteers with
the most severe disease symptoms also showed the largest post-
infection rise in NK activation to the HA of the challenge strain. Plasma
samples from subjects withmoderate/severe symptoms following labo-
ratory inﬂuenza challenge also demonstrated increased NK-92 activa-
tion to the HAs of two homosubtypic viruses post-infection. This
suggests that symptomatic human inﬂuenza infection can induce
cross-reactive NK cell activating Abs that recognize antigenically dis-
tinct viruses and potentially promote heterologous immunity, as we
previously described in macaques (Jegaskanda et al., 2013c).
Natural symptomatic but not experimental inﬂuenza infection in-
creased Ab-mediated NK cell activation to the internal protein M1 and
to a lesser extent NP. Donor infection history, strain/subtype of infectingvirus, route of infection and infectious dose may affect the capacity of
a given inﬂuenza infection to boost Ab-dependent NK cell activation.
During natural inﬂuenza infection Ab-dependent NK cell activation
was increased to the HA of the infecting virus and M1 following sero-
conversion. Surprisingly, when the NK cell activating Abs to HA and
M1were serially diluted it was revealed that in some cases the endpoint
titres were identical in pre- and post-seroconversion samples. These re-
sults suggest that the total levels of NK cell activating Abs were not in-
creased post-seroconversion but that the Abs induced or expanded
after seroconversion are more potent activators of NK cells. This could
be due to a number of factors including enhanced Ab avidity for its
Ag or altered glycosylation of the IgG Fc region, which can change the
binding afﬁnity for Fc receptors (Ferrara et al., 2006; Ferrara et al.,
2011; Shinkawa et al., 2003) and lead to altered immune effector func-
tions like ADCC. Differential Fc glycosylation or increased Ab avidity
post-seroconversionmay explain the observation that NK cell activation
at a single IgG concentration is variable in samples that demonstrate
similar quantities of NK cell activating Abs by titration.
The role of NK cell activating Abs to internal inﬂuenza proteins in
the control of inﬂuenza infection is controversial. Animal models of
inﬂuenza infection suggest that Abs to conserved Ags like M1 and
NP are important for heterosubtypic immunity (LaMere et al., 2011b).
Likewise, passive transfer of immune serum from mice vaccinated
with NP into naïve or B-cell deﬁcient mice decreased inﬂuenza
viral load (Carragher et al., 2008). Since Abs to internal inﬂuenza Ags
cannot prevent viral entry by neutralisation (Gerhard et al., 1997;
Mozdzanowska et al., 1999), anti-NP IgG activity is likely mediated
through complex interactions with effector cells (LaMere et al.,
2011b). In B cell deﬁcient mice the antiviral action of NP reactive
Abs is Fc receptor dependent and signiﬁcantly reduced in Fc receptor
γ-common chain knockout (FcRγ−/−) mice (LaMere et al., 2011b).
The nature of these antiviral effects and their relevance to human
inﬂuenza infection is unclear. Speciﬁcally it is unknown if M1 and NP
Abs activate effector cells that directly kill infected targets (ADCC)
or act indirectly by cytokine-mediated stimulation of other antiviral
cell types.
Indeed, this study found NK cell activating Abs to highly conserved
inﬂuenza Ags, but we were not able to detect Ab-mediated killing of
target cells infected with rVVs expressing either NP or M1. Internal in-
ﬂuenza proteins are present in the extracellular environment following
their release from dead or infected cells (LaMere et al., 2011b) and NP
is present on the surface of inﬂuenza-infected cells in vitro as early as
one hour post-infection (Bodewes et al., 2013; Virelizier et al., 1977;
Yewdell et al., 1981). In spite of a robust rVV infection system as evi-
denced by consistently high levels of ADCC against rVV-HA infected
cells, we found that only a small percentage (up to ~25%) of target
CEM cells infected with rVV-NP had NP on the cell surface, which may
be insufﬁcient for detection of Ab-mediated killing in the assays
employed. Inﬂuenza and vaccinia viruses differ in genome composition,
replication cycle and tissue tropism therefore it is not known if the rVV
expression system accurately reﬂects an in vivo inﬂuenza infection.
Inﬂuenza-infected cells have been shown to express relatively low
levels of surface NP compared to surface glycoproteins HA and NA,
which were approximately 10-fold more abundant (Yewdell et al.,
1981). Future studies using inﬂuenza-infected cells as targets in
Ab-mediated killing assays would be informative, but such assays are
problematic since inﬂuenza-infected cells are susceptible to HA and
NA-speciﬁc ADCC in polyclonal serum. To carry out Ab-mediated killing
assays speciﬁcally targeting surface NP and M1 on inﬂuenza-infected
cells would require monoclonal Abs (mAbs) with known ADCC activity.
However most currently available mAbs are not isolated with their
native Fc regions and glycosylation patterns, which can signiﬁcantly
impact ADCC functionality (Arnold et al., 2007; Mahan et al., 2016;
Vidarsson et al., 2014).
Apart from opsonising infected cells the Abs may also form circu-
lating immune complexes (ICs) by opsonising soluble M1 and NP.
289H.A. Vanderven et al. / EBioMedicine 8 (2016) 277–290These circulating ICs may activate NK cells or other effectors to en-
hance immune responses. Innate immune cell activation by circulating
ICs would lead to the release of pro-inﬂammatory cytokines and
chemokines capable of activating and recruiting different effector cell
types (macrophages, neutrophils and T-cells) as reported in the mouse
infection model.
Collectively, inﬂuenza-exposed humanshave detectableNK cell acti-
vating Abs to highly conserved internal inﬂuenza proteins. M1 and NP
reactive Abs are capable of mediating robust NK cell activation and de-
granulation, enhancing the local immune response to inﬂuenza. Further,
inﬂuenza infection boosts NK cell activating Abs to the HA of the in-
fecting virus and induces cross-reactive Abs to theHAs of homosubtypic
inﬂuenza viruses. We speculate that opsonising Abs to both surface and
internal proteins are capable of activating NK cells or other innate Fc re-
ceptor expressing effectors to confer some level of heterologous inﬂuen-
za protection in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.029.
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